Successful case of adjunctive intravenous bacteriophage therapy to treat left ventricular assist device infection

We read with interest the study of Gallagher and Baker.1 The study highlighted antimicrobial resistance (AMR) and formation of biofilms of abiotic surfaces as significant challenges in healthcare facilities. Indeed, left ventricular assist device (LVAD) associated infections are difficult to treat, especially during long-term support, with documented infection rates ranging from 25 to 80%.2 Driveline exit site infections remain one of the major complications and pose risk of ascending to the pump, causing deep-seated and life-threatening infections.